Vasily Mamonov Selected Research

Factor IX (Coagulation Factor IX)

1/2020	Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.
1/2020	Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vasily Mamonov Research Topics

Disease

4	Hemophilia A (Haemophilia) 05/2021 - 01/2017
3	Hemorrhage 01/2021 - 01/2016
2	Hemophilia B (Haemophilia B) 01/2020 - 01/2020
1	Body Weight (Weight, Body) 01/2017

Drug/Important Bio-Agent (IBA)

3	Hemostatics (Antihemorrhagics)IBA 01/2020 - 01/2017
2	fitusiranIBA 01/2021 - 01/2017
2	AntithrombinsIBA 01/2021 - 01/2017
2	Factor IX (Coagulation Factor IX)FDA LinkGeneric 01/2020 - 01/2020
1	Factor VIII (Coagulation Factor VIII)IBA 05/2021
1	Small Interfering RNA (siRNA)IBA 01/2021
1	gamma-AIBA 01/2020
1	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 01/2020
1	prothrombin complex concentrates (PPSB)IBA 01/2020
1	IsoantibodiesIBA 01/2017
1	Blood Coagulation Factors (Coagulation Factor)IBA 01/2017
1	Thrombin FDA Link 01/2017
1	AntibodiesIBA 01/2016

Therapy/Procedure

2	Therapeutics 05/2021 - 01/2021
2	Subcutaneous Injections 01/2021 - 01/2017
1	Injections 01/2017
1	RNAi Therapeutics 01/2017
1	Intravenous Infusions 01/2017
1	Minor Surgical Procedures (Minor Surgery) 01/2016